36 Antibody

What are the main types of "36 Antibodies" relevant to research applications?

Three primary types of 36 antibodies appear in scientific literature, each targeting distinct proteins with different biological functions:

• IL-36α/IL-1F6 Antibody: Targets interleukin 1 family member #6, a cytokine involved in inflammatory signaling pathways. This 158 amino acid protein presents as an 18 kDa monomer in cell lysates and is uniquely expressed in monocytes, B cells, and T cells (notably, it's the only novel IL-1 family member expressed on T-cells) .

• Connexin-36 Antibody: Targets the connexin-36 protein that forms gap junction channels primarily in neuronal cells. These antibodies recognize specific epitopes, such as those within the C-terminal cytoplasmic domain (in the case of clone 2D22) or the intracellular loop (amino acids 170-182 in rat Connexin-36) .

• IL-36R Antibody: Targets the interleukin-36 receptor (also known as IL1RL2), which mediates interleukin-36-dependent activation of NF-kappa-B and MAPK pathways. This receptor is expressed predominantly in epithelial barriers and participates in local inflammatory responses .

How do IL-36 family proteins structurally and functionally relate to other interleukin family members?

IL-36 proteins share key structural and functional characteristics with other IL-1 family members:

• Structural features: All IL-1 family members exhibit a 12 β-strand, β-trefoil configuration, believed to have arisen from a common ancestral gene through multiple duplications .

• Sequence homology: Human IL-36α shares 30% amino acid identity with IL-1ra, 27% with IL-1β, 31% with IL-36Ra, 36% with IL-1F7, 46% with IL-36β, 57% with IL-36γ, and 28% with IL-1F10 .

• Signaling mechanism: Like IL-1 and IL-18, IL-36α engages a binding receptor (IL-1Rrp2) which then recruits a second receptor component (IL-1RAcP) to form an active heterodimeric receptor complex .

• Pathway activation: IL-36 cytokines activate NF-κB and MAPK pathways in an IL-1Rrp2-dependent manner, similar to other IL-1 family members, leading to inflammatory responses .

What expression patterns characterize Connexin-36 in the mammalian nervous system?

Connexin-36 (Cx36) shows distinct expression patterns in the mammalian nervous system:

• Cell type specificity: Predominantly expressed in neuronal cells (unlike many other connexins found in glial cells) .

• Regional distribution: Highly expressed in the inferior olive, cerebellar cortex, olfactory bulbs, several brainstem nuclei, CA3 subregion of the hippocampus, and reticular thalamic nuclei .

• Spinal cord expression: Present in motoneurons of adult rat spinal cord and appears in processes along the first layer of the dorsal horn .

• Brainstem localization: Detected in hypoglossal motoneurons, as demonstrated by co-localization with SMI 32, a motoneuron marker .

What validated applications exist for IL-36α antibodies in laboratory research?

Western blot represents the primary validated application for IL-36α/IL-1F6 antibodies:

• Sample detection: Successfully detects IL-36α in lysates of human cells transfected with the protein, with a specific band appearing at approximately 16 kDa .

• Optimal concentration: Effective detection at dilutions of 1 μg/mL when used with HRP-conjugated secondary antibodies .

• Specificity confirmation: Side-by-side comparison of mock-transfected versus IL-36α-transfected cell lysates provides validation of antibody specificity .

• Buffer conditions: Optimal results achieved under reducing conditions using appropriate immunoblot buffer systems .

What methods are recommended for optimizing Connexin-36 antibody performance in immunohistochemistry?

For optimal immunohistochemical detection of Connexin-36:

• Tissue preparation: Perfusion-fixed frozen sections yield superior results for preserving Cx36 epitopes and accessibility .

• Dilution optimization: Antibody concentrations of approximately 1:300 have been validated for rat spinal cord and brainstem sections .

• Visualization strategy: Use fluorescent secondary antibodies with complementary markers (e.g., DAPI for nuclei, SMI 32 for motoneurons) to establish cellular context .

• Specificity controls: Include preincubation with Connexin-36 blocking peptide as a negative control to confirm signal specificity .

• Target structures: Focus on neuronal processes and cell bodies in regions with known high expression of Cx36, such as the dorsal horn of spinal cord or hypoglossal motoneurons in brainstem .

How should researchers design experiments to evaluate IL-36R antibody efficacy in disease models?

When designing experiments to evaluate IL-36R antibody efficacy:

• Model selection: Choose appropriate disease models where IL-36 signaling plays a role, such as inflammatory skin conditions like atopic dermatitis .

• Outcome measures: Use validated clinical assessment tools (e.g., Eczema Area and Severity Index for AD) to quantify disease severity changes .

• Control groups: Include placebo controls with matching administration schedules (e.g., the spesolimab study used a 2:1 randomization to active drug or placebo) .

• Treatment protocol: Establish appropriate dosing regimens (e.g., 600 mg intravenous doses every 4 weeks as used in the spesolimab trial) .

• Duration: Allow sufficient time to observe treatment effects (the spesolimab trial evaluated outcomes at 16 weeks) .

• Concomitant medications: Consider designing sensitivity analyses to account for effects of rescue medications (as seen in the spesolimab study where excluding patients who used restricted corticosteroids revealed a more pronounced treatment effect) .

What factors most commonly affect specificity in Western blot applications of 36 antibodies?

Several factors can influence Western blot specificity when working with 36 antibodies:

• Antibody concentration: Titration is essential, with recommended dilutions ranging from 1:200 for Connexin-36 to 1:10,000 for certain Connexin-36 clones in PANC-1 cell lysates .

• Sample preparation: Proper preparation of tissue lysates or membrane fractions is critical; mouse and rat brain membranes have been successfully used for Connexin-36 detection .

• Denaturation conditions: Reducing conditions are recommended for IL-36α detection, with specific band detection at approximately 16 kDa .

• Cross-reactivity concerns: Consider potential cross-reactivity with structurally similar proteins, particularly for IL-36 family members that share sequence homology .

• Species specificity: Verify antibody reactivity across species - for example, Connexin-36 antibodies may show differential binding between human, rat, and mouse samples .

How can researchers differentiate between specific and non-specific binding in immunohistochemical applications?

To distinguish specific from non-specific binding:

• Blocking peptide controls: Compare staining patterns with and without preincubation with specific blocking peptides (as demonstrated for Connexin-36 antibody) .

• Negative controls: Include sections processed without primary antibody to identify background from secondary antibodies.

• Anatomical distribution: Verify that staining patterns match known expression profiles (e.g., Connexin-36 in specific brain regions including inferior olive and cerebellar cortex) .

• Co-localization studies: Confirm co-expression with established cell-type markers (e.g., SMI 32 for motoneurons in Connexin-36 studies) .

• Signal intensity gradient: Compare expression levels across tissues with known differential expression of the target protein.

What strategies should researchers employ when analyzing therapeutic effects of IL-36 pathway inhibition?

For rigorous analysis of IL-36 pathway inhibition:

• Primary endpoint selection: Choose clinically relevant endpoints (the spesolimab trial used percentage change from baseline in EASI score) .

• Statistical approach: Determine appropriate statistical tests and significance thresholds before study initiation .

• Sensitivity analyses: Plan predefined sensitivity analyses to address potential confounding factors (e.g., concomitant medication use) .

• Effect size interpretation: Consider both statistical significance and clinical meaningfulness of observed differences (the spesolimab study found an adjusted mean difference of -25.6%, p=0.149 for the primary analysis) .

• Subgroup analyses: Evaluate treatment effects in different patient populations to identify those most likely to benefit.

• Safety assessment: Thoroughly evaluate the safety profile alongside efficacy data (spesolimab was noted to be well tolerated with no clinically relevant safety signals) .

What emerging roles have been identified for Connexin-36 in neurological function and pathology?

Connexin-36 plays several important roles in neurological processes:

• Neural development: Involvement in neuronal neurogenesis and neural fertility control .

• Sleep regulation: Participation in the regulation of waking and sleep states .

• Excitotoxicity: Role in N-methyl-D-aspartate-mediated neuronal death following neuronal injury .

• Seizure mechanisms: Confirmed involvement in the generation and maintenance of seizure activity in both human and animal studies .

• Neural circuit function: Formation of electrical synapses that enable direct communication between neurons, facilitating synchronized activity in neuronal networks.

How does the IL-36 signaling pathway contribute to inflammatory skin disorders?

The IL-36 pathway plays several roles in inflammatory skin conditions:

• Epithelial barrier function: The IL-36 signaling system appears to be particularly active in epithelial barriers, participating in local inflammatory responses .

• Cytokine network: IL-36 signaling induces the IL-23/IL-17/IL-22 pathway, which is implicated in several inflammatory skin diseases .

• Therapeutic target: Targeting IL-36R with antibodies like spesolimab represents a novel approach for treating inflammatory skin conditions such as atopic dermatitis .

• Clinical evidence: The first evaluation of IL-36 pathway inhibition in atopic dermatitis showed numerical improvements in disease severity, suggesting a mechanistic role in disease pathogenesis .

• Differentiation from other approaches: IL-36 pathway inhibition differs from broad-spectrum immunosuppressive approaches (like cyclosporin A) and Janus kinase inhibition, potentially offering a more targeted therapeutic strategy .

What methodological approaches can researchers use to study IL-36 and IL-36R interactions at the molecular level?

To investigate IL-36/IL-36R interactions at the molecular level:

• Binding assays: Affinity binding assays can determine binding kinetics and affinity constants (KD values around 1.1 x 10-6 have been reported for certain antibody-peptide interactions) .

• Structural analysis: Study the formation of the heterodimeric receptor complex consisting of IL-36R and the coreceptor IL1RAP .

• Activation assessment: Measure activation of downstream signaling pathways including NF-κB and MAPK following receptor engagement .

• Epitope mapping: Use synthetic peptides representing different regions of IL-36 proteins to map binding interfaces with receptors and antibodies .

• Functional studies: Evaluate biological responses in cell systems expressing IL-36R and IL1RAP following stimulation with IL-36 cytokines and/or blockade with anti-IL-36R antibodies .

What potential exists for developing more specific antibodies targeting novel epitopes in IL-36 family proteins?

Opportunities for developing next-generation IL-36 antibodies include:

• Isoform-specific targeting: Designing antibodies that selectively recognize IL-36α, IL-36β, or IL-36γ with minimal cross-reactivity.

• Functional domain targeting: Creating antibodies that specifically block receptor-ligand interactions without affecting other protein functions.

• Post-translational modification sensitivity: Developing antibodies that distinguish between different post-translationally modified forms of IL-36 proteins.

• Species cross-reactivity optimization: Engineering antibodies with controlled cross-reactivity profiles for translational research spanning preclinical and clinical applications.

• Bispecific approaches: Exploring bispecific antibodies that simultaneously target IL-36R and complementary inflammatory pathways.

How might combination therapies incorporating IL-36 pathway inhibition enhance treatment of inflammatory disorders?

Potential for combination therapy approaches:

• Synergistic pathway targeting: Combining IL-36R blockade with inhibition of complementary inflammatory pathways (e.g., IL-17, IL-23, JAK-STAT).

• Sequential therapy: Using IL-36 pathway inhibitors to induce initial response followed by maintenance therapy with different mechanisms.

• Targeted delivery systems: Developing tissue-specific delivery of anti-IL-36R antibodies to enhance local effects while minimizing systemic exposure.

• Biomarker-guided approach: Identifying patient subpopulations most likely to benefit from IL-36 pathway inhibition based on molecular profiling.

• Reduced immunosuppression: Leveraging the more targeted nature of IL-36 pathway inhibition to potentially reduce broad immunosuppression seen with conventional therapies .

What novel applications of Connexin-36 antibodies could advance understanding of neuronal network dysfunction in disease states?

Novel applications for Connexin-36 research:

• Circuit-specific mapping: Using Connexin-36 antibodies to map electrical synapses in specific neural circuits affected in neurological disorders.

• Development of biomarkers: Evaluating changes in Connexin-36 expression patterns as potential diagnostic or prognostic markers in neurological diseases.

• Therapeutic target validation: Determining whether modulation of Connexin-36 function could offer neuroprotection or seizure control.

• Imaging applications: Developing in vivo imaging approaches using labeled Connexin-36 antibodies to visualize gap junction distribution non-invasively.

• Single-cell analysis: Combining Connexin-36 immunolabeling with single-cell transcriptomics to correlate electrical coupling with gene expression profiles.

What are the key differences between antibodies targeting the IL-36 ligands versus the IL-36 receptor?

Key differences between anti-IL-36 ligand and anti-IL-36R antibodies:

How should researchers select the appropriate antibody when studying Connexin-36 across different experimental contexts?

Selection criteria for Connexin-36 antibodies: